Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Want to see STRO full AI Analyst Report?
Top Page
Sutro Biopharma
(NASDAQ:STRO)
Select Model
Select Model
Rating:48Neutral
Price Target:
$31.00
▼(-1.74% Downside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (heavy cash burn, deep losses, and negative equity). Technicals are mixed with neutral momentum, while valuation is constrained by negative earnings. Corporate events modestly help due to improved runway and pipeline/partner progress, but do not fully offset the fundamental risk profile.
Positive Factors
Proprietary cell-free platform
Sutro's XpressCF cell-free protein synthesis platform is a durable technical moat enabling rapid, precise protein engineering. This platform shortens discovery timelines, supports differentiated ADC and engineered biologic design, and underpins recurring collaboration demand and licensing revenue over multiple programs.
Negative Factors
Heavy negative operating cash flow
Sutro's persistent ~-$151.6M TTM operating cash burn forces continuous external financing to support operations. This structural cash consumption heightens dilution and execution risk: if clinical or partner milestones slip, the company may need additional equity or partnership funding within the medium term, stressing continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary cell-free platform
Sutro's XpressCF cell-free protein synthesis platform is a durable technical moat enabling rapid, precise protein engineering. This platform shortens discovery timelines, supports differentiated ADC and engineered biologic design, and underpins recurring collaboration demand and licensing revenue over multiple programs.
Read all positive factors
Sutro Biopharma (STRO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$571.35M
Dividend YieldN/A
Average Volume (3M)987.85K
Price to Earnings (P/E)―
Beta (1Y)3.52
Revenue Growth49.94%
EPS Growth44.76%
CountryUS
Employees269
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.49
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit2.45
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$47.50Price Target Upside50.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-8.97
Revenue Forecast (FY)$32.87M
Sutro Biopharma Business Overview & Revenue Model
Company Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specif...
How the Company Makes Money
Sutro primarily generates revenue through collaboration and licensing arrangements rather than product sales, because it is a clinical-stage company and does not have null. Key revenue streams generally include (1) upfront payments received when e...
Sutro Biopharma Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
31
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.61M | 102.48M | 62.04M | 153.73M | 67.77M | 61.88M |
| Gross Profit | 98.33M | 95.16M | 54.83M | 146.91M | 59.48M | 52.11M |
| EBITDA | -106.70M | -97.63M | -180.45M | -67.92M | -105.07M | -97.56M |
| Net Income | -153.60M | -191.09M | -227.46M | -106.79M | -119.20M | -105.54M |
Balance Sheet | ||||||
| Total Assets | 241.99M | 173.83M | 387.21M | 470.74M | 406.94M | 341.41M |
| Cash, Cash Equivalents and Short-Term Investments | 202.56M | 141.43M | 316.89M | 375.62M | 334.36M | 197.94M |
| Total Debt | 13.63M | 15.67M | 23.15M | 33.63M | 55.02M | 57.37M |
| Total Liabilities | 308.88M | 306.28M | 342.61M | 321.09M | 189.90M | 88.84M |
| Stockholders Equity | -66.89M | -132.45M | 44.60M | 149.65M | 217.05M | 252.56M |
Cash Flow | ||||||
| Free Cash Flow | -152.14M | -178.93M | -194.64M | -115.93M | -4.31M | -97.00M |
| Operating Cash Flow | -151.61M | -177.23M | -191.54M | -111.62M | 3.55M | -81.68M |
| Investing Cash Flow | 16.01M | 45.01M | 218.51M | -3.92M | -35.02M | -97.31M |
| Financing Cash Flow | 103.05M | 44.00K | 94.05M | 137.55M | 48.31M | 3.26M |
Sutro Biopharma Technical Analysis
Positive
31.55
Price Trends
30.18
Positive
23.08
Positive
16.11
Positive
Market Momentum
1.25
Positive
40.82
Neutral
5.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STRO, the sentiment is Positive. The current price of 31.55 is below the 20-day moving average (MA) of 36.60, above the 50-day MA of 30.18, and above the 200-day MA of 16.11, indicating a neutral trend. The MACD of 1.25 indicates Positive momentum. The RSI at 40.82 is Neutral, neither overbought nor oversold. The STOCH value of 5.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STRO.
Sutro Biopharma Risk Analysis
Sutro Biopharma disclosed 78 risk factors in its most recent earnings report. Sutro Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sutro Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $39.61M | -1.39 | -170.86% | ― | -100.00% | 13.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $571.35M | -2.12 | 275.30% | ― | 49.94% | 44.76% | |
47 Neutral | $70.11M | -0.90 | -80.35% | ― | ― | 27.27% | |
44 Neutral | $28.15M | -1.15 | -136.08% | ― | -77.56% | -50.38% | |
40 Underperform | $24.07M | -0.75 | -208.23% | ― | -100.00% | 26.30% |
* Healthcare Sector Average
STRO
Sutro Biopharma
31.13
22.75
271.39%
CRVO
CervoMed
3.24
-5.27
-61.93%
ACET
Adicet Bio
7.76
-3.44
-30.71%
INMB
Inmune Bio
1.41
-6.05
-81.10%
HOWL
Werewolf Therapeutics
0.44
-0.64
-59.44%
Sutro Biopharma Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Sutro Biopharma Ends ATM Agreement After 2025 Results
Positive
Mar 23, 2026
On March 23, 2026, Sutro Biopharma reported full-year 2025 results and announced the mutual termination of its at-the-market equity sales agreement with Jefferies, closing a potential source of incremental share issuance. The company highlighted p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.